# Amber

> RNA-based multi-kilobase gene editing platform for diseases with high allelic diversity.

## Why it is interesting

Amber Bio edits RNA instead of DNA for reversible, multi-kilobase corrections — Broad/Berkeley founders targeting mutation-diverse diseases where one drug can cover many variants.

## Profile

- **Stage:** seed
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Seed (Aug 2023): $26M co-led by Playground Global and a16z Bio + Health; ARCH Venture Partners, Eli Lilly, RDF, Hummingbird, Pillar VC participated (Business Wire)
- Platform: multi-kilobase RNA editing for allelic-diverse genetic diseases (Amber Bio site)
- Co-investors not in VCT directory: Playground Global, Eli Lilly, RDF, Hummingbird Ventures, Pillar VC

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/arch-venture-partners

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/amber